These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Correlation of imatinib resistance with the mutational status of KIT and PDGFRA genes in gastrointestinal stromal tumors: a meta-analysis. Lee JH; Kim Y; Choi JW; Kim YS J Gastrointestin Liver Dis; 2013 Dec; 22(4):413-8. PubMed ID: 24369323 [TBL] [Abstract][Full Text] [Related]
5. Kinase mutations and imatinib mesylate response for 64 Taiwanese with advanced GIST: preliminary experience from Chang Gung Memorial Hospital. Yeh CN; Chen TW; Lee HL; Liu YY; Chao TC; Hwang TL; Jan YY; Chen MF Ann Surg Oncol; 2007 Mar; 14(3):1123-8. PubMed ID: 17195905 [TBL] [Abstract][Full Text] [Related]
6. A prospective, multicenter, phase 2 study of imatinib mesylate in korean patients with metastatic or unresectable gastrointestinal stromal tumor. Ryu MH; Kang WK; Bang YJ; Lee KH; Shin DB; Ryoo BY; Roh JK; Kang JH; Lee H; Kim TW; Chang HM; Park JO; Park YS; Kim TY; Kim MK; Lee WK; Kang HJ; Kang YK Oncology; 2009; 76(5):326-32. PubMed ID: 19307738 [TBL] [Abstract][Full Text] [Related]
7. Familial gastrointestinal stromal tumor syndrome: report of 2 cases with KIT exon 11 mutation. Jones DH; Caracciolo JT; Hodul PJ; Strosberg JR; Coppola D; Bui MM Cancer Control; 2015 Jan; 22(1):102-8. PubMed ID: 25504284 [TBL] [Abstract][Full Text] [Related]
8. [Gastrointestinal stromal tumor of small intestine associated with lymph node metastasis: a report of 2 cases with review of literatures]. Kong M; Wang YL; Xu LJ; Teng XD Zhonghua Bing Li Xue Za Zhi; 2009 Sep; 38(9):617-20. PubMed ID: 20079191 [TBL] [Abstract][Full Text] [Related]
9. Clonal evolution of resistance to imatinib in patients with metastatic gastrointestinal stromal tumors. Desai J; Shankar S; Heinrich MC; Fletcher JA; Fletcher CD; Manola J; Morgan JA; Corless CL; George S; Tuncali K; Silverman SG; Van den Abbeele AD; van Sonnenberg E; Demetri GD Clin Cancer Res; 2007 Sep; 13(18 Pt 1):5398-405. PubMed ID: 17875769 [TBL] [Abstract][Full Text] [Related]
10. Predictive factors for long-term effects of imatinib therapy in patients with inoperable/metastatic CD117(+) gastrointestinal stromal tumors (GISTs). Rutkowski P; Nowecki ZI; Debiec-Rychter M; Grzesiakowska U; Michej W; Woźniak A; Siedlecki JA; Limon J; vel Dobosz AJ; Kakol M; Osuch C; Ruka W J Cancer Res Clin Oncol; 2007 Sep; 133(9):589-97. PubMed ID: 17458563 [TBL] [Abstract][Full Text] [Related]
11. c-Kit/PDGFRA gene status alterations possibly related to primary imatinib resistance in gastrointestinal stromal tumors. Miselli FC; Casieri P; Negri T; Orsenigo M; Lagonigro MS; Gronchi A; Fiore M; Casali PG; Bertulli R; Carbone A; Pierotti MA; Tamborini E; Pilotti S Clin Cancer Res; 2007 Apr; 13(8):2369-77. PubMed ID: 17438095 [TBL] [Abstract][Full Text] [Related]
12. [Secondary mutation of c-kit/PDGFRα genotypes after imatinib mesylate therapy and its relationship with efficacy of sunitinib]. Hong JL; Li J; Li J; Shen L Zhonghua Bing Li Xue Za Zhi; 2012 Jun; 41(6):386-90. PubMed ID: 22932406 [TBL] [Abstract][Full Text] [Related]
13. High-resolution melting analysis is a sensitive diagnostic tool to detect imatinib-resistant and imatinib-sensitive PDGFRA exon 18 mutations in gastrointestinal stromal tumors. Künstlinger H; Binot E; Merkelbach-Bruse S; Huss S; Wardelmann E; Buettner R; Schildhaus HU Hum Pathol; 2014 Mar; 45(3):573-82. PubMed ID: 24444465 [TBL] [Abstract][Full Text] [Related]
14. [Study on the mechanism of imatinib-induced resistance in gastrointestinal stromal tumors]. Zhou Y; Hou YY; Tan YS; Lu SH; Hou J; Liu JL; Qin J; Shen KT; Sun YH Zhonghua Zhong Liu Za Zhi; 2009 Aug; 31(8):597-601. PubMed ID: 20021947 [TBL] [Abstract][Full Text] [Related]
15. Mechanisms of resistance to imatinib and sunitinib in gastrointestinal stromal tumor. Wang WL; Conley A; Reynoso D; Nolden L; Lazar AJ; George S; Trent JC Cancer Chemother Pharmacol; 2011 Jan; 67 Suppl 1():S15-24. PubMed ID: 21181476 [TBL] [Abstract][Full Text] [Related]
17. Fluorescence in situ hybridization analysis and immunophenotyping of c-Kit/PDGFRA and Bcl-2 expression in gastrointestinal stromal tumors. Orsenigo M; Brich S; Riva C; Conca E; Bertulli R; Dileo P; Gronchi A; Casali PG; Pierotti MA; Tamborini E; Pilotti S Anal Quant Cytol Histol; 2010 Aug; 32(4):225-33. PubMed ID: 21434524 [TBL] [Abstract][Full Text] [Related]
18. Cas-L was overexpressed in imatinib-resistant gastrointestinal stromal tumor cells. Thao le B; Vu HA; Yasuda K; Taniguchi S; Yagasaki F; Taguchi T; Watanabe T; Sato Y Cancer Biol Ther; 2009 Apr; 8(8):683-8. PubMed ID: 19417561 [TBL] [Abstract][Full Text] [Related]
19. Imatinib efficacy by tumor genotype in Korean patients with advanced gastrointestinal stromal tumors (GIST): The Korean GIST Study Group (KGSG) study. Kang HJ; Ryu MH; Kim KM; Park YS; Choi J; Ryoo BY; Kim WH; Im SA; Bang YJ; Park SH; Lee JH; Chung IJ; Bae HI; Kim JG; Lee KH; Song HS; Kwon HC; Baek JH; Shin DB; Lee KE; Kang YK Acta Oncol; 2012 Apr; 51(4):528-36. PubMed ID: 22150077 [TBL] [Abstract][Full Text] [Related]
20. Molecular research directions in the management of gastrointestinal stromal tumors. Tarn C; Godwin AK Curr Treat Options Oncol; 2005 Nov; 6(6):473-86. PubMed ID: 16242052 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]